CV Manifestations With BTK, CAR-T and Immunotherapies

Join Dr Mazyar Shadman (University of Washington, US), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) as they explore the latest advancements and challenges in managing cardiovascular manifestations in patients undergoing targeted therapies like Bruton's Tyrosine Kinase (BTK) inhibitors, Chimeric Antigen Receptor T-cell (CAR-T) therapies and cutting-edge immunotherapies. 

The faculty will discuss emerging evidence, clinical strategies and innovative treatments aimed at improving patient outcomes. Register now to secure your spot in this upcoming webinar focused on the intersection of cardiovascular health and modern immuno-oncology.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by  Eli Lilly through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.